DE60028361D1 - Verfahren und zusammensetzungen zur karzinomdiagnose - Google Patents

Verfahren und zusammensetzungen zur karzinomdiagnose

Info

Publication number
DE60028361D1
DE60028361D1 DE60028361T DE60028361T DE60028361D1 DE 60028361 D1 DE60028361 D1 DE 60028361D1 DE 60028361 T DE60028361 T DE 60028361T DE 60028361 T DE60028361 T DE 60028361T DE 60028361 D1 DE60028361 D1 DE 60028361D1
Authority
DE
Germany
Prior art keywords
mra
mesothelin
compositions
subject
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60028361T
Other languages
English (en)
Other versions
DE60028361T2 (de
Inventor
B Scholler
Ingegerd Hellstrom
Erik Hellstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PACIFIC NORTHWEST RES INST SEA
Original Assignee
PACIFIC NORTHWEST RES INST SEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PACIFIC NORTHWEST RES INST SEA filed Critical PACIFIC NORTHWEST RES INST SEA
Publication of DE60028361D1 publication Critical patent/DE60028361D1/de
Application granted granted Critical
Publication of DE60028361T2 publication Critical patent/DE60028361T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60028361T 1999-02-26 2000-02-25 Verfahren und zusammensetzungen zur karzinomdiagnose Expired - Lifetime DE60028361T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12176799P 1999-02-26 1999-02-26
US121767P 1999-02-26
US14740499P 1999-08-05 1999-08-05
US147404P 1999-08-05
PCT/US2000/004834 WO2000050900A2 (en) 1999-02-26 2000-02-25 Methods and compositions for diagnosing carcinomas

Publications (2)

Publication Number Publication Date
DE60028361D1 true DE60028361D1 (de) 2006-07-06
DE60028361T2 DE60028361T2 (de) 2007-05-10

Family

ID=26819780

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60028361T Expired - Lifetime DE60028361T2 (de) 1999-02-26 2000-02-25 Verfahren und zusammensetzungen zur karzinomdiagnose

Country Status (8)

Country Link
EP (1) EP1169645B1 (de)
JP (3) JP4813661B2 (de)
AT (1) ATE328280T1 (de)
AU (1) AU3007200A (de)
CA (1) CA2369433A1 (de)
DE (1) DE60028361T2 (de)
ES (1) ES2269105T3 (de)
WO (1) WO2000050900A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
WO2004006837A2 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
US20040180387A1 (en) * 2003-03-13 2004-09-16 Fujirebio Diagnostics, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
CA2534659A1 (en) * 2003-08-05 2005-02-17 Morphotek, Inc. A variant cell surface molecule associated with cancer
US20060014221A1 (en) * 2004-01-21 2006-01-19 Fujirebio Diagnostics, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of mesothelioma
US20060014211A1 (en) * 2004-01-21 2006-01-19 Fujirebio Diagnostics, Inc. Detection of mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of the peritoneum and the peritoneal cavity
EP3026119B1 (de) 2006-01-04 2019-09-18 Fujirebio America, Inc. Verwendung von he4 und anderen biochemischen markern zur analyse von ovarialkrebserkrankungen
JP5207437B2 (ja) * 2006-06-27 2013-06-12 独立行政法人理化学研究所 中皮由来組織特異的マーカーの同定及び検出方法
KR101554848B1 (ko) 2007-10-01 2015-09-21 브리스톨-마이어스 스큅 컴퍼니 메소텔린에 결합하는 인간 항체 및 이의 용도
CA2706529C (en) * 2007-11-26 2016-10-25 Bayer Schering Pharma Aktiengesellschaft Anti-mesothelin antibodies and uses therefor
US8481297B2 (en) 2009-01-08 2013-07-09 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
WO2011032003A1 (en) 2009-09-10 2011-03-17 Yale University Immunization to reduce neurotoxicity during treatment with cytolytic viruses
WO2011056993A1 (en) 2009-11-04 2011-05-12 Yale University Compositions and methods for treating cancer with attenuated oncolytic viruses
US10874621B2 (en) 2013-10-17 2020-12-29 The Brigham And Women's Hospital, Inc. Cationic nanoparticles for co-delivery of nucleic acids and therapeutic agents
WO2015172149A1 (en) 2014-05-09 2015-11-12 Yale University Hyperbranched polyglycerol-coated particles and methods of making and using thereof
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
US20180126014A1 (en) 2015-04-15 2018-05-10 Yale University Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof
WO2017095751A1 (en) 2015-12-02 2017-06-08 Partikula Llc Compositions and methods for modulating cancer cell metabolism
US20190117799A1 (en) 2016-04-01 2019-04-25 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
CN106248767B (zh) * 2016-07-15 2018-12-07 济南大学 一种用于检测癌细胞中h2s的三维纸分析器件的制备方法
WO2018053434A1 (en) 2016-09-16 2018-03-22 The Johns Hopkins University Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery
US20200085758A1 (en) 2016-12-16 2020-03-19 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
US20230140818A1 (en) 2017-04-27 2023-05-04 The University Of Hong Kong Use of hcn inhibitors for treatment of cancer
US11478433B2 (en) 2017-06-23 2022-10-25 Yale University Nanomaterials with enhanced drug delivery efficiency
WO2023010060A2 (en) 2021-07-27 2023-02-02 Novab, Inc. Engineered vlrb antibodies with immune effector functions
WO2023147552A1 (en) 2022-01-28 2023-08-03 University Of Georgia Research Foundation, Inc. Radiosensitizing compositions and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2093928C (en) * 1990-10-12 2000-02-29 Mark C. Willingham Monoclonal antibodies for detection and treatment of cancer
IL107366A (en) * 1992-10-23 2003-03-12 Chugai Pharmaceutical Co Ltd Genes coding for megakaryocyte potentiator
AU703769B2 (en) * 1996-01-05 1999-04-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Mesothelium antigen and methods and kits for targeting it

Also Published As

Publication number Publication date
WO2000050900A3 (en) 2001-08-23
CA2369433A1 (en) 2000-08-31
JP4813661B2 (ja) 2011-11-09
WO2000050900A2 (en) 2000-08-31
JP2010096774A (ja) 2010-04-30
EP1169645A2 (de) 2002-01-09
JP2011206062A (ja) 2011-10-20
DE60028361T2 (de) 2007-05-10
AU3007200A (en) 2000-09-14
EP1169645B1 (de) 2006-05-31
JP2002538434A (ja) 2002-11-12
ES2269105T3 (es) 2007-04-01
ATE328280T1 (de) 2006-06-15

Similar Documents

Publication Publication Date Title
DE60028361D1 (de) Verfahren und zusammensetzungen zur karzinomdiagnose
CN102695716B (zh) 肝病病情指标糖链标记物
ATE426167T1 (de) Auto-antikírper gegen annexin-proteine als marker fur lungenkrebs
RU2004109149A (ru) Диагностика карцином
JP2011524013A (ja) 大麻の使用の検出
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
CN109406778A (zh) 一种检测烟叶中青枯病菌的时间分辨荧光定量试纸条及其制备方法和应用
EP0970377B1 (de) Diagnose von epithelzellabnormitäten
WO2006004958A3 (en) Detection or measurement of antibodies to antigenic proteins in biological tissues or samples
EP1007570A4 (de) Monospezifische antikörper gegen fibrinogen und fibrinopeptide
JP2004323508A (ja) 抗重金属モノクローナル抗体およびその使用方法
CN106119340B (zh) 一种脱‑γ‑羧基凝血酶原的检测方法、检测试剂和检测试剂盒
DE69428998T2 (de) Reagenzien und verfahren zur detektion und quantitativen bestimmung von testosteron in flüssigen proben
CN108333361A (zh) 桥连有抗体的磁性微球复合制剂及其制备方法与应用
CN108603883A (zh) 前列腺癌的判定方法
JP2002508835A (ja) 細胞内蛋白質抗原および血清中の特異的細胞内蛋白質抗原に対する抗体の存在を同定するための方法
CN113880948B (zh) 抗ca724抗体或其抗原结合片段及其制备方法和应用
ATE432469T1 (de) Auf immunreaktion gegen boris basierendes verfahren für den nachweis von krebs
DE69829587D1 (de) Nukleinsäuremoleküle, die mit dem schwachen rhesus-d phänotyp korrelieren
SE0202702L (sv) Immunotest för specifik bestämning av SCCA isoformer
JPWO2006112482A1 (ja) Ｃ型肝炎ウイルス感染に関連する肝疾患の予後の予測
KR100737186B1 (ko) 항-에스트리올 항혈청을 포함하는 에스트리올 검출용바이오센서 및 에스트리올 검출방법
WO2004112694A3 (en) Immunogenic reagents from west nile virus
DE60131962D1 (de) Verfahren und zusammensetzungen zum nachweis von taenia solium larven mittels eines klonierten antigens
DE69830174D1 (de) Antikörper und sonstige bindungsmoleküle gegen hepatitis b virusantigene

Legal Events

Date Code Title Description
8364 No opposition during term of opposition